ASX:CSLBiotechs
How Investors May Respond To CSL (ASX:CSL) Gaining Canadian Approval for ANDEMBRY in Rare Disease Market
CSL recently announced that Health Canada granted marketing authorization for ANDEMBRY (garadacimab), a monoclonal antibody for the routine prevention of hereditary angioedema attacks in patients aged 12 years and older.
This regulatory milestone gives CSL access to the Canadian HAE market with a product that showed very large reductions in attack frequency and sustained safety in pivotal studies.
We'll examine how ANDEMBRY's approval in Canada could strengthen CSL's position and growth...